Archemix, Isis Pharmaceuticals Ink Aptamer Drug Discovery Deal

Archemix and Isis Pharmaceuticals announced they have entered into an alliance that includes a broad intellectual property license agreement and research collaboration.

According to Archemix and Isis, the agreement provides Archemix with access to approximately four hundred issued and pending Isis patents covering proprietary chemistries, analytical methods and manufacturing methods related to the R&D and commercialization of oligonucleotide-based therapeutics to discover and develop drugs based on Archemix’s proprietary SELEX technology.

The companies did not disclose specific financial terms.